Changes in f4fc22f: Added overview headers to files wihtout; Formatting

				ACTG1.md
			
          @@ -6,6 +6,9 @@ link-citations: true

           [[_TOC_]]

          +

          +## Overview

          +

           ACTG1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) affected by aberrant somatic hypermutation in B-cell lymphomas. The function of mutations in ACTB and ACTG1 have not yet been determined.[@witjesPrevalenceCytoplasmicActin2020]

				BLK.md
			
          @@ -3,7 +3,6 @@ bibliography: 'morinlab.bib'

           csl: 'NLM.csl'

           link-citations: true

           ---

          -# BLK

           ## Relevance tier by entity

				BTBD3.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHeterogeneityDiffuse2013] and by the same group in a subsequent study.[@reddyGeneticFunctionalDrivers2017] It remains in Tier 2 because other exome and genome-wide studies of DLBCL did not reproduce this observation.

				FAS.md
			
          @@ -7,7 +7,7 @@ link-citations: true

           ## Overview

           FAS encodes a cell surface receptor involved in the induction of apoptosis. FAS mutations are common in DLBCL and may be more frequent in primary gastric DLBCL.[@wohlfartFASCD95Mutations2004],[@schollMutationsRegionFAS2007]

          -Mutations also occur in FL at a lower rate.[@morinFrequentMutationHistonemodifying2011] Although reported in one BL study,[[@paneaWholeGenomeLandscape2019] overall the evidence for FAS mutations in BL remains sparse. 

          +Mutations also occur in FL at a lower rate.[@morinFrequentMutationHistonemodifying2011] Although reported in one BL study,[@paneaWholeGenomeLandscape2019] overall the evidence for FAS mutations in BL remains sparse. 

           Mutations in FAS often lead to a loss of function, making lymphoma cells resistant to Fas ligand-induced apoptosis, 

           thereby allowing malignant cells to evade immune surveillance.[@rysFasMutationsNonHodgkins2019]

           In mouse models, Fas mutations led to a significantly shorter lymphoma-specific survival and reduced sensitivity to chemotherapy.[@rysFasMutationsNonHodgkins2019]

				HLA-DQA1.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschmann et al.[@hubschmannMutationalMechanismsShaping2021]

				ID3.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           ID3 was first reported as mutated in BL in 2012 by Richter et al.[@richterRecurrentMutationID32012] 

           The existence of mutations in DLBCL were described in 2012 by Schmitz et al[@schmitzBurkittLymphomaPathogenesis2012] and later in MZL by Spina et al.[@spinaGeneticsNodalMarginal2016]

				IKBKE.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschmann et al.[[@hubschmannMutationalMechanismsShaping2021]]

				INO80.md
			
          @@ -5,6 +5,7 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

           Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHeterogeneityDiffuse2013] and by the same group in a subsequent study.[@reddyGeneticFunctionalDrivers2017] It remains in Tier 2 because other exome and genome-wide studies of DLBCL did not reproduce this observation.

				JUP.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           Mutations in this gene were first described in FL in 2021 by Hübschmann et al.[@hubschmannMutationalMechanismsShaping2021]

				LAPTM5.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschmann et al.[@hubschmannMutationalMechanismsShaping2021]

				NFKBIE.md
			
          @@ -6,7 +6,7 @@ link-citations: true

           [[_TOC_]]

           ## Overview

          -NFKBIE encodes IκBε, a negative regulator of NF-κB. Mutations in NFKBIE can disrupt this regulatory function, leading to constitutive activation of NF-κB signaling.<sup>1</sup> Mutations are relatively common in DLBCL and MCL.[@morinGeneticLandscapesRelapsed2016]

          +NFKBIE encodes IκBε, a negative regulator of NF-κB. Mutations in NFKBIE can disrupt this regulatory function, leading to constitutive activation of NF-κB signaling.[@mansouriFrequentNFKBIEDeletions2016] Mutations are relatively common in DLBCL and MCL.[@morinGeneticLandscapesRelapsed2016]

				PNPO.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschmann et al.[@hubschmannMutationalMechanismsShaping2021]

				RBM6.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschmann et al.[@hubschmannMutationalMechanismsShaping2021]

				RFX7.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           First described as mutated in BL in 2009 by Grande et al.[@grandeGenomewideDiscoverySomatic2019]

				SETD2.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHeterogeneityDiffuse2013] and by the same group in a subsequent study.[@reddyGeneticFunctionalDrivers2017] It remains in Tier 2 because other exome and genome-wide studies of DLBCL did not reproduce this observation.

				STAT5B.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHeterogeneityDiffuse2013] and by the same group in a subsequent study.[@reddyGeneticFunctionalDrivers2017] It remains in Tier 2 because other exome and genome-wide studies of DLBCL did not reproduce this observation.

				TFAP4.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           Mutations in BL were first described by Grande et al.[@grandeGenomewideDiscoverySomatic2019]

				UBR5.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHeterogeneityDiffuse2013] and by the same group in a subsequent study.[@reddyGeneticFunctionalDrivers2017] It remains in Tier 2 because other exome and genome-wide studies of DLBCL did not reproduce this observation.

				ZEB2.md
			
          @@ -5,6 +5,8 @@ link-citations: true

           ---

           [[_TOC_]]

          +## Overview

          +

           Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHeterogeneityDiffuse2013] and by the same group in a subsequent study.[@reddyGeneticFunctionalDrivers2017] It remains in Tier 2 because other exome and genome-wide studies of DLBCL did not reproduce this observation.

...	...	@@ -6,6 +6,9 @@ link-citations: true
6	6
7	7	[[_TOC_]]
8	8
	9	+
	10	+## Overview
	11	+
9	12	ACTG1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) affected by aberrant somatic hypermutation in B-cell lymphomas. The function of mutations in ACTB and ACTG1 have not yet been determined.[@witjesPrevalenceCytoplasmicActin2020]
10	13
11	14

...	...	@@ -3,7 +3,6 @@ bibliography: 'morinlab.bib'
3	3	csl: 'NLM.csl'
4	4	link-citations: true
5	5	---
6		-# BLK
7	6
8	7	## Relevance tier by entity
9	8

...	...	@@ -5,6 +5,8 @@ link-citations: true
5	5	---
6	6	[[_TOC_]]
7	7
	8	+## Overview
	9	+
8	10	Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHeterogeneityDiffuse2013] and by the same group in a subsequent study.[@reddyGeneticFunctionalDrivers2017] It remains in Tier 2 because other exome and genome-wide studies of DLBCL did not reproduce this observation.
9	11
10	12

...	...	@@ -7,7 +7,7 @@ link-citations: true
7	7
8	8	## Overview
9	9	FAS encodes a cell surface receptor involved in the induction of apoptosis. FAS mutations are common in DLBCL and may be more frequent in primary gastric DLBCL.[@wohlfartFASCD95Mutations2004],[@schollMutationsRegionFAS2007]
10		-Mutations also occur in FL at a lower rate.[@morinFrequentMutationHistonemodifying2011] Although reported in one BL study,[[@paneaWholeGenomeLandscape2019] overall the evidence for FAS mutations in BL remains sparse.
	10	+Mutations also occur in FL at a lower rate.[@morinFrequentMutationHistonemodifying2011] Although reported in one BL study,[@paneaWholeGenomeLandscape2019] overall the evidence for FAS mutations in BL remains sparse.
11	11	Mutations in FAS often lead to a loss of function, making lymphoma cells resistant to Fas ligand-induced apoptosis,
12	12	thereby allowing malignant cells to evade immune surveillance.[@rysFasMutationsNonHodgkins2019]
13	13	In mouse models, Fas mutations led to a significantly shorter lymphoma-specific survival and reduced sensitivity to chemotherapy.[@rysFasMutationsNonHodgkins2019]

...	...	@@ -5,6 +5,7 @@ link-citations: true
5	5	---
6	6	[[_TOC_]]
7	7
	8	+## Overview
8	9
9	10	Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHeterogeneityDiffuse2013] and by the same group in a subsequent study.[@reddyGeneticFunctionalDrivers2017] It remains in Tier 2 because other exome and genome-wide studies of DLBCL did not reproduce this observation.
10	11

...	...	@@ -6,7 +6,7 @@ link-citations: true
6	6	[[_TOC_]]
7	7
8	8	## Overview
9		-NFKBIE encodes IκBε, a negative regulator of NF-κB. Mutations in NFKBIE can disrupt this regulatory function, leading to constitutive activation of NF-κB signaling.<sup>1</sup> Mutations are relatively common in DLBCL and MCL.[@morinGeneticLandscapesRelapsed2016]
	9	+NFKBIE encodes IκBε, a negative regulator of NF-κB. Mutations in NFKBIE can disrupt this regulatory function, leading to constitutive activation of NF-κB signaling.[@mansouriFrequentNFKBIEDeletions2016] Mutations are relatively common in DLBCL and MCL.[@morinGeneticLandscapesRelapsed2016]
10	10
11	11
12	12